Drug discovery company Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Department of Neurosciences, KU Leuven have signed a research collaboration with Ipsen to advance drug discovery efforts in Parkinson’s disease.
The collaboration will evaluate investigational compounds in multiple pharmacology models for Parkinson’s disease.
Oncodesign’s discovery activities head and chief scientific officer Dr Jan Hoflack said; "Our partnership with Ipsen on the discovery of novel therapeutic agents in Parkinson’s disease has advanced to a stage where we can use further in depth expertise and advanced pharmacology models to position our leads."
In January 2012, Ipsen and Oncodesign entered into a research collaboration for the development of new therapeutic agents against LRKK2 involved in Parkinson’s disease, corresponding to the focus in neurology and movement disorders.
As per the agreement, Oncodesign and LNGT will work together to progress the Parkinson’s disease programme to clinical development.
Oncodesign will offer financial support required to carry out research activities by LNGT.
LNGT believes that the collaboration with Oncodesign is a perfect example of translational research in action.
Ipsen chief scientific officer, R&D executive vice president Dr Claude Bertrand said; "The Oncodesign collaboration with LNGT will greatly accelerate the progress of this research program."